Diabetes Canada has recently updated their Guidelines for Pharmacotherapy and CKD.
QUEST makes it easy to see how your practice aligns with the latest guidelines—and where to improve.
Guidelines Updates at a Glance
Pharmacotherapy
SGLT2 inhibitors or GLP-1 receptor agonists are now recommended for patients with T2D and cardiovascular disease or multiple CV risk factors — even when A1C is at target.
—
Chronic Kidney Disease
Prioritize SGLT2 inhibitors for kidney protection. Add a GLP-1RA if additional blood sugar or weight control is needed.
—
Testing
eGFR and urine ACR testing are required at diagnosis and annually, with more frequent testing (every 3–6 months) if CKD or albuminuria is present.
—
Read the new
Your Personalized QUEST Report
A confidential, practice-level snapshot aligned with the 2025 guideline updates.
Insights on patients with T2D who also have CVD, CKD, or may be missing recommended therapies or kidney function testing.
Clear direction on where your practice is aligned — and where quality improvement opportunities exist.
Powered by Experts in Primary Care, Data, and Education
QUEST is a collaboration between organizations committed to streamlining traditional QI processes to remove barriers to participation.
ICI Medical – Program design, management, and implementation.
Amplify Care – Data Collection and Analysis
AFHTO – Primary Care Champions
LMC Healthcare - Medical education on QI in specialty care
-
"Our members see huge opportunity in QUEST. We’ve done our due diligence and know it will add real value for family physicians."
Jess Rogers | CEO, AFHTO
-
“When clinicians see their own data, it sparks change — not because someone told them to, but because they see it themselves.”
Ted Alexander | VP, Amplify Care
-
Quote
Quote source
Join QUEST Today
Register now to receive your personalized report.